Cost-Effectiveness of Colonoscopy in Screening for Colorectal Cancer

  1. Amnon Sonnenberg, MD, MSc;
  2. Fabiola Delcò, MD, MPH; and
  3. John M. Inadomi, MD
  1. From the Department of Veterans Affairs Medical Center and the University of New Mexico, Albuquerque, New Mexico.
    1. Figure 1.
      View larger version:
      Figure 1. Influence of compliance with repeated fecal occult blood testing (FOBT) once per year (left) and repeated colonoscopy (right) once per decade on the incremental cost-effectiveness ratio compared with no screening.
    2. Figure 2.
      View larger version:
      Figure 2. Influence of the sensitivity and specificity of fecal occult blood testing (FOBT) on the incremental cost-effectiveness ratio compared with no screening.
    3. Figure 3.
      View larger version:
      Figure 3. Efficacy of colonoscopy in preventing colorectal cancer and its influence on the incremental cost-effectiveness ratio of fecal occult blood testing (dotted line) and colonoscopy (solid line) compared with no screening.
    4. Appendix Figure. The black and gray ovals represent Markov states in which patients remain for at least a full 1-year cycle. The white ovals represent intermediate states of screening procedures, which patients may enter and leave during one cycle. The arrows represent transitions between various states.
      View larger version:
      Appendix Figure. The black and gray ovals represent Markov states in which patients remain for at least a full 1-year cycle. The white ovals represent intermediate states of screening procedures, which patients may enter and leave during one cycle. The arrows represent transitions between various states. Markov states in screening for colorectal cancer (CRC) by fecal occult blood test (FOBT) (top), flexible sigmoidoscopy (middle), and colonoscopy (bottom).

    Summary for Patients

    « Previous | Next Article »Table of Contents